A New Frontier
Deep Learning Diagnostic for Skin Malignancy
Bostel Technologies is a clinical-stage healthcare company that has developed Melody, a patent-pending unique Dual Deep Learning technology in order to facilitate the diagnosis of skin cancer by dermoscopy.
Skin cancers are the most frequent
About 1 million non-melanoma skin cancers and 288,000 malignant melanoma (MM) cancers occurred globally in 2018. One in every three cancers diagnosed is a skin cancer and, according to Skin Cancer Foundation Statistics, one in every five Americans will develop skin cancer in their lifetime.
An issue of growing importance
Longer living, lifestyle choice favoring sun exposure and depletion of the protective ozone layer are leading to a rapid increase in skin cancer. With a growing segment of the population aged 60 and above and thinning ozone layers, the number of Melanoma cases is projected by The WHO to increase by +30% by 2030
Significant unmet medical need
Skin cancer diagnosis is burdensome to both patients and health care professionals, resulting in a strong need for a more effective platform for skin cancer detection. Today, about 30 biopsies are performed to detect one melanoma.
How the Technology Works
Skin Cancer Diagnosis by Dual Deep Learning Technology
Bostel is Intended For
Hospitals, clinics and medical centers
Pharmacies and point of care locations
Payers and healthcare insurers
Team of Experts
Pioneered by Leading Authorities
We have leveraged sonification and artificial intelligence to create a new diagnostic paradigm with clinically-proven sensitivity and specificity. This patent-pending platform will empower healthcare professionals to efficiently and effectively diagnose melanoma lesions using dermoscopy so they can focus on improving outcomes and helping their patients.Contact Us